Health Trials

About this trial

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.

Eligibility criteria

Qualifiers

Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.

Informed Consent Signed.

Disqualifiers

Patient life expectancy less than 12 months.

Contraindication for antiplatelet therapy.

Not meet inclusion criteria.

Trial design

Treatments tested in this trial

  • Sequent Please Neo

Treatment groups

2,028 Participants
are divided into 1 treatment group

Locations

27
Hospital Universitario de Araba01009, Alava Spain
Hospital General Universitario de Alicante Dr.Balmis03010, Alicante Spain
Hospital Universitario de Badajoz06080, Badajoz Spain
Hospital Universitari Germans Trias I Pujol08916, Badalona Spain

Sponsors and collaborators

Fundación EPIC

Lead sponsor

Source ClinicalTrials.gov